Shares in Amazon ( AMZN) are up nearly 46% over the past year, with the stock hitting a record high closing price of $238.15 ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Crypto is in a cooling period after running to a new record last week and was pulled lower by the DeepSeek-driven sell-off in tech stocks.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

S&P 500 futures steady after record highs. Novo Nordisk and Twilio surge, while Boeing posts $4B loss. Traders eye Fed policy ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Novo Nordisk said that patients taking a higher ... The shakeup in the AI space has spread waves across the stock market. Here’s what investors need to know. Top investment firms expect non ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.